REGENXBIO (NASDAQ:RGNX) Rating Reiterated by Chardan Capital

Chardan Capital restated their buy rating on shares of REGENXBIO (NASDAQ:RGNXGet Rating) in a report issued on Monday morning, Zacks.com reports.

Other equities research analysts have also issued reports about the stock. Wedbush initiated coverage on shares of REGENXBIO in a report on Wednesday, December 15th. They issued a neutral rating and a $29.00 price objective for the company. Zacks Investment Research upgraded shares of REGENXBIO from a sell rating to a hold rating in a research report on Wednesday, February 16th. StockNews.com began coverage on shares of REGENXBIO in a research note on Thursday, March 31st. They issued a hold rating on the stock. Morgan Stanley upped their price target on REGENXBIO from $50.00 to $51.00 and gave the company an overweight rating in a research report on Wednesday, March 23rd. Finally, TheStreet raised shares of REGENXBIO from a d rating to a c rating in a research report on Tuesday, March 1st. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, REGENXBIO presently has an average rating of Hold and an average price target of $46.88.

Shares of NASDAQ:RGNX opened at $30.52 on Monday. The firm has a market capitalization of $1.31 billion, a PE ratio of 11.14 and a beta of 1.06. REGENXBIO has a 52-week low of $24.09 and a 52-week high of $46.46. The firm has a fifty day moving average of $28.86 and a 200 day moving average of $31.35.

REGENXBIO (NASDAQ:RGNXGet Rating) last posted its quarterly earnings data on Tuesday, March 1st. The biotechnology company reported $6.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.28 by $2.39. The firm had revenue of $398.66 million during the quarter, compared to analysts’ expectations of $255.76 million. REGENXBIO had a return on equity of 22.35% and a net margin of 27.18%. The company’s revenue for the quarter was up 1759.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.24) EPS. Equities analysts predict that REGENXBIO will post -3.87 earnings per share for the current fiscal year.

Several hedge funds have recently bought and sold shares of RGNX. BlackRock Inc. boosted its position in shares of REGENXBIO by 3.3% during the fourth quarter. BlackRock Inc. now owns 6,571,438 shares of the biotechnology company’s stock valued at $214,884,000 after buying an additional 209,635 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of REGENXBIO by 20.9% in the fourth quarter. JPMorgan Chase & Co. now owns 5,004,773 shares of the biotechnology company’s stock worth $163,656,000 after acquiring an additional 864,447 shares during the period. State Street Corp grew its stake in shares of REGENXBIO by 2.6% in the fourth quarter. State Street Corp now owns 2,490,253 shares of the biotechnology company’s stock worth $81,431,000 after acquiring an additional 62,815 shares during the period. RTW Investments LP lifted its position in REGENXBIO by 5.0% during the third quarter. RTW Investments LP now owns 1,845,366 shares of the biotechnology company’s stock valued at $77,358,000 after purchasing an additional 87,623 shares during the period. Finally, Sofinnova Investments Inc. boosted its holdings in REGENXBIO by 690.1% in the fourth quarter. Sofinnova Investments Inc. now owns 1,008,081 shares of the biotechnology company’s stock worth $32,964,000 after purchasing an additional 880,488 shares during the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

REGENXBIO Company Profile (Get Rating)

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.

Featured Articles

Analyst Recommendations for REGENXBIO (NASDAQ:RGNX)

Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.